CONMED Stock Price, News & Analysis (NASDAQ:CNMD)

$60.67 +0.26 (+0.43 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$60.41
Today's Range$59.78 - $60.71
52-Week Range$39.74 - $64.99
Volume157,256 shs
Average Volume192,910 shs
Market Capitalization$1.67 billion
P/E Ratio72.23
Dividend Yield1.32%
Beta0.74

About CONMED (NASDAQ:CNMD)

CONMED logoCONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company's product lines consist of orthopedic surgery, general surgery and surgical visualization. As of December 31, 2016, the Company's products are distributed domestically directly to over 6,000 hospitals, surgery centers and other healthcare institutions, as well as through medical specialty distributors. The Company's orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. These products are marketed under a range of brands, including Hall, CONMED Linvatec, Concept and Shutt.

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNASDAQ:CNMD
CUSIP20741010
Phone+1-315-6243215

Debt

Debt-to-Equity Ratio0.84%
Current Ratio2.56%
Quick Ratio1.49%

Price-To-Earnings

Trailing P/E Ratio72.2289156626506
Forward P/E Ratio28.35
P/E Growth2.46

Sales & Book Value

Annual Sales$796.39 million
Price / Sales2.13
Cash Flow$3.78 per share
Price / Cash16.07
Book Value$20.87 per share
Price / Book2.91

Profitability

Trailing EPS$0.83
Net Income$55.48 million
Net Margins6.97%
Return on Equity9.15%
Return on Assets3.97%

Miscellaneous

Employees3,300
Outstanding Shares27,930,000

CONMED (NASDAQ:CNMD) Frequently Asked Questions

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Tuesday, November 28th. Investors of record on Friday, December 15th will be given a dividend of $0.20 per share on Friday, January 5th. This represents a $0.80 annualized dividend and a dividend yield of 1.32%. The ex-dividend date of this dividend is Thursday, December 14th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) posted its quarterly earnings data on Wednesday, January, 31st. The medical technology company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.65 by $0.04. The medical technology company earned $222.60 million during the quarter, compared to the consensus estimate of $212.17 million. CONMED had a return on equity of 9.15% and a net margin of 6.97%. The company's revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.54 EPS. View CONMED's Earnings History.

When will CONMED make its next earnings announcement?

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its FY18 earnings guidance on Wednesday, January, 31st. The company provided earnings per share guidance of $2.11-2.17 for the period, compared to the Thomson Reuters consensus estimate of $2.07. The company issued revenue guidance of $828.2-836.2 million, compared to the consensus revenue estimate of $808.57 million.

Where is CONMED's stock going? Where will CONMED's stock price be in 2018?

4 equities research analysts have issued 1 year price objectives for CONMED's shares. Their forecasts range from $46.00 to $71.00. On average, they anticipate CONMED's stock price to reach $55.00 in the next twelve months. View Analyst Ratings for CONMED.

What are Wall Street analysts saying about CONMED stock?

Here are some recent quotes from research analysts about CONMED stock:

  • 1. According to Zacks Investment Research, "CONMED has had a favorable run on the bourses over the last year. Notably, the company delivered stellar performance in the fourth-quarter. Strength in General Surgery business on the back of strong performances by Advanced Surgical and Endoscopic Technologies buoys optimism. We are also upbeat about the favorable foreign exchange movements. Solid revenue guidance is indicative of brighter prospects. CONMED is also benefiting from the increasing trend of using minimally invasive techniques as a large percentage of the company’s products are designed for these procedures. On the flipside, company operates in a highly competitive environment. Lower healthcare spending buoyed by the ongoing political conundrum in the U.S. healthcare space is a headwind. CONMED’s stock looks much overvalued at the moment." (2/2/2018)
  • 2. Needham & Company LLC analysts commented, "We hosted investor meetings in Boston with CNMD’s CEO and CFO earlier this week. We believe that CNMD is making progress in its turnaround, as evidenced by its organic revenue growth of 3% year-to-date (YTD), which is a considerable improvement from the bottom of (3%) growth in 2H14. We expect further improvement in its domestic Orthopedic Surgery business as new products continue to gain momentum and believe that this can push overall revenue growth towards 5%. We also believe that margin expansion will be the next chapter in the CNMD story given higher revenue growth, a reduced currency headwind, and a renewed focus on cost reductions. CNMD’s operating margin is currently around 9% and we see potential for this to reach the mid-teens or higher over time. We think the stock looks undervalued at a P/E of 25.5x our 2018E estimate considering that we think its potential earnings power is $3.00+ per share and we reiterate our Buy rating." (11/17/2017)

Who are some of CONMED's key competitors?

Who are CONMED's key executives?

CONMED's management team includes the folowing people:

  • Mark E. Tryniski, Independent Chairman of the Board (Age 56)
  • Curt R. Hartman, President, Chief Executive Officer, Director (Age 53)
  • Todd W. Garner, Chief Financial Officer, Executive Vice President
  • Patrick J. Beyer, President of CONMED International (Age 51)
  • Daniel S. Jonas, Executive Vice President - Legal Affairs, General Counsel (Age 53)
  • Heather L. Cohen, Executive Vice President - Human Resources, Secretary (Age 44)
  • Wilfredo Ruiz-Caban, Executive Vice President - Quality Assurance, Regulatory Affairs and Operations (Age 52)
  • Peter K. Shagory, Executive Vice President - Strategy and Corporate Development (Age 48)
  • Nathan Folkert, Vice President, General Manager - U.S. Orthopedics Business (Age 42)
  • John E. Kennedy, Vice President and General Manager - U.S. Endoscopic Technologies (Age 59)

Who owns CONMED stock?

CONMED's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.75%), Victory Capital Management Inc. (7.97%), Champlain Investment Partners LLC (5.29%), Goldman Sachs Group Inc. (3.82%), Cramer Rosenthal Mcglynn LLC (3.65%) and Macquarie Group Ltd. (2.71%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, John L Workman, Luke A Pomilio, Mark D Snyder and Mark E Tryniski. View Institutional Ownership Trends for CONMED.

Who sold CONMED stock? Who is selling CONMED stock?

CONMED's stock was sold by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Gotham Asset Management LLC, Bank of New York Mellon Corp, Needham Investment Management LLC, Martingale Asset Management L P, Bessemer Group Inc., Metropolitan Life Insurance Co. NY and Huber Capital Management LLC. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Dirk Kuyper, Jo Ann Golden and Luke A Pomilio. View Insider Buying and Selling for CONMED.

Who bought CONMED stock? Who is buying CONMED stock?

CONMED's stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Assenagon Asset Management S.A., Goldman Sachs Group Inc., Hudson Bay Capital Management LP, Victory Capital Management Inc., Deutsche Bank AG and Citadel Advisors LLC. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen, John L Workman and Mark E Tryniski. View Insider Buying and Selling for CONMED.

How do I buy CONMED stock?

Shares of CONMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CONMED's stock price today?

One share of CONMED stock can currently be purchased for approximately $60.67.

How big of a company is CONMED?

CONMED has a market capitalization of $1.67 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $0.83 on an earnings per share basis. CONMED employs 3,300 workers across the globe.

How can I contact CONMED?

CONMED's mailing address is 525 French Rd, UTICA, NY 13502-5945, United States. The medical technology company can be reached via phone at +1-315-6243215.


MarketBeat Community Rating for CONMED (CNMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CONMED (NASDAQ:CNMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.252.252.25
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $55.00$50.67$50.67$49.33
Price Target Upside: 4.81% downside2.41% downside2.41% downside0.29% upside

CONMED (NASDAQ:CNMD) Consensus Price Target History

Price Target History for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2018Needham & Company LLCBoost Price TargetBuy -> Buy$58.00 -> $71.00HighView Rating Details
11/3/2017KeyCorpReiterated RatingHoldN/AView Rating Details
11/3/2017Piper Jaffray CompaniesReiterated RatingHold$46.00N/AView Rating Details
4/27/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> Neutral$50.00 -> $48.00HighView Rating Details
11/23/2016Leerink SwannReiterated RatingHold -> NeutralN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

CONMED (NASDAQ:CNMD) Earnings History and Estimates Chart

Earnings by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ CNMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/24/2018$0.44N/AView Earnings Details
1/31/2018Q4 2017$0.65$0.69$212.17 million$222.60 millionViewN/AView Earnings Details
11/2/2017Q3 2017$0.41$0.42$187.13 million$190.10 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.41$0.41$194.50 million$197.20 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.35$0.38$181.47 million$186.57 millionViewN/AView Earnings Details
2/1/2017Q416$0.56$0.54$204.04 million$204.10 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.41$180.13 million$184.79 millionViewListenView Earnings Details
7/27/2016Q216$0.46$0.47$191.48 million$193.40 millionViewListenView Earnings Details
4/27/2016Q116$0.41$0.42$180.15 million$181.20 millionViewListenView Earnings Details
1/27/2016Q415$0.51$0.52$191.03 million$191.00 millionViewListenView Earnings Details
10/21/2015Q315$0.44$0.38$173.96 million$169.20 millionViewListenView Earnings Details
7/21/2015Q215$0.44$0.36$182.40 million$181.00 millionViewListenView Earnings Details
4/22/2015Q115$0.41$0.42$176.16 million$177.90 millionViewListenView Earnings Details
1/27/2015Q414$0.54$0.53$196.00 million$195.00 millionViewListenView Earnings Details
10/23/2014Q314$0.39$0.44$173.30 million$175.00 millionViewListenView Earnings Details
7/23/2014Q214$0.47$0.47$190.62 million$188.20 millionViewListenView Earnings Details
4/24/2014Q1$0.47$0.49$191.95 million$181.90 millionViewListenView Earnings Details
2/13/2014Q413$0.49$0.53$197.24 million$203.40 millionViewListenView Earnings Details
10/24/2013Q313$0.40$0.40$186.20 million$179.30 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.44$0.43$193.55 million$193.00 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.45$0.45$196.79 million$187.00 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.50$0.52$200.12 million$201.20 millionViewListenView Earnings Details
10/25/2012$0.40$0.43ViewN/AView Earnings Details
7/26/2012$0.45$0.43ViewN/AView Earnings Details
4/26/2012$0.44$0.43ViewN/AView Earnings Details
2/15/2012$0.39$0.46ViewN/AView Earnings Details
10/27/2011$0.31$0.33ViewN/AView Earnings Details
7/28/2011$0.35$0.35ViewN/AView Earnings Details
4/28/2011$0.31$0.37ViewN/AView Earnings Details
2/3/2011$0.36$0.36ViewN/AView Earnings Details
10/28/2010Q3 2010$0.28$0.34ViewN/AView Earnings Details
7/29/2010Q2 2010$0.26$0.32ViewN/AView Earnings Details
4/29/2010Q1 2010$0.26$0.28ViewN/AView Earnings Details
2/4/2010Q4 2009$0.32$0.37ViewN/AView Earnings Details
10/22/2009Q3 2009$0.17$0.28ViewN/AView Earnings Details
7/30/2009Q2 2009$0.16$0.17ViewN/AView Earnings Details
4/23/2009Q1 2009$0.24$0.19ViewN/AView Earnings Details
2/5/2009Q4 2008$0.30$0.34ViewN/AView Earnings Details
10/23/2008Q3 2008$0.34$0.37ViewN/AView Earnings Details
7/24/2008Q2 2008$0.39$0.43ViewN/AView Earnings Details
4/24/2008Q1 2008$0.35$0.38ViewN/AView Earnings Details
2/7/2008Q4 2007$0.38$0.44ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

CONMED (NASDAQ:CNMD) Earnings Estimates

2018 EPS Consensus Estimate: $2.14
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.42$0.43$0.43
Q2 20182$0.45$0.50$0.48
Q3 20182$0.47$0.48$0.48
Q4 20182$0.74$0.79$0.77
(Earnings estimates data provided by Zacks Investment Research)

Dividends

CONMED (NASDAQ:CNMD) Dividend Information

Most Recent Dividend:1/5/2018
Annual Dividend:$0.80
Dividend Yield:1.32%
Payout Ratio:96.39% (Trailing 12 Months of Earnings)
37.38% (Based on This Year's Estimates)
33.33% (Based on Next Year's Estimates)
Dividend Payments by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/28/2017quarterly$0.201.48%12/14/201712/15/20171/5/2018
8/29/2017quarterly$0.201.65%9/14/20179/15/201710/5/2017
5/24/2017quarterly$0.201.6%6/13/20176/15/20177/5/2017
2/28/2017quarterly$0.201.92%3/13/20173/15/20174/5/2017
11/21/2016quarterly$0.201.77%12/13/201612/15/20161/5/2017
8/25/2016quarterly$0.201.99%9/13/20169/15/201610/5/2016
5/25/2016quarterly$0.202.05%6/13/20166/15/20167/6/2016
2/23/2016quarterly$0.202.1%3/11/20163/15/20164/5/2016
11/16/2015quarterly$0.201.92%12/11/201512/15/20151/5/2016
8/24/2015quarterly$0.201.53%9/11/20159/15/201510/5/2015
5/29/2015quarterly$0.201.44%6/11/20156/15/20157/6/2015
2/25/2015quarterly$0.201.56%3/12/20153/16/20154/6/2015
11/18/2014quarterly$0.201.92%12/11/201412/15/20141/5/2015
8/25/2014quarterly$0.202.11%9/11/20149/15/201410/6/2014
5/23/2014quarterly$0.201.8%6/12/20146/16/20147/7/2014
2/27/2014quarterly$0.201.72%3/13/20143/17/20144/7/2014
10/28/2013quarterly$0.2012/12/201312/16/20131/6/2014
8/27/2013quarterly$0.151.91%9/12/20139/16/201310/4/2013
5/24/2013quarterly$0.151.76%6/13/20136/17/20137/8/2013
2/27/2013quarterly$0.151.93%3/13/20133/15/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

CONMED (NASDAQ CNMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.62%
Institutional Ownership Percentage: 98.57%
Insider Trades by Quarter for CONMED (NASDAQ:CNMD)
Institutional Ownership by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ CNMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/12/2018Luke A. PomilioCFOSell1,962$60.25$118,210.50View SEC Filing  
2/1/2018Jo Ann GoldenDirectorSell3,000$63.90$191,700.00View SEC Filing  
2/1/2018Luke A. PomilioCFOSell18,023$63.38$1,142,297.74View SEC Filing  
1/3/2018Charles FarkasDirectorBuy158$50.61$7,996.3811,707View SEC Filing  
11/9/2017Luke A PomilioEVPSell29,363$50.70$1,488,704.1045,486View SEC Filing  
11/7/2017Luke A PomilioCFOSell12,429$50.63$629,280.2745,486View SEC Filing  
11/3/2017Luke A PomilioEVPSell10,020$53.57$536,771.4044,472View SEC Filing  
10/3/2017Charles FarkasDirectorBuy148$53.96$7,986.0811,549View SEC Filing  
8/14/2017Jo Ann GoldenDirectorSell3,000$50.00$150,000.0019,782View SEC Filing  
7/5/2017Charles FarkasDirectorBuy157$50.78$7,972.4611,401View SEC Filing  
6/13/2017Dirk KuyperDirectorSell1,000$52.24$52,240.0010,739View SEC Filing  
5/15/2017Daniel JonasEVPSell3,000$51.22$153,660.0014,455View SEC Filing  
4/3/2017Charles FarkasDirectorBuy180$44.41$7,993.808,505View SEC Filing  
3/13/2017Heather L CohenEVPBuy440$40.00$17,600.0011,291View SEC Filing  
3/10/2017Curt R HartmanCEOBuy8,030$40.11$322,083.3036,470View SEC Filing  
3/6/2017Mark E TryniskiDirectorBuy5,000$41.15$205,750.0027,000View SEC Filing  
1/3/2017Charles FarkasDirectorBuy305$44.65$13,618.258,325View SEC Filing  
11/8/2016Daniel JonasEVPSell1,500$41.78$62,670.0016,590View SEC Filing  
11/7/2016Daniel JonasEVPSell2,555$40.40$103,222.0020,120View SEC Filing  
10/3/2016Charles FarkasDirectorBuy336$40.04$13,453.448,020View SEC Filing  
7/1/2016Charles FarkasDirectorBuy282$47.87$13,499.347,684View SEC Filing  
6/3/2016Luke A PomilioCFOSell4,400$41.56$182,864.0041,884View SEC Filing  
4/1/2016Charles FarkasDirectorBuy338$42.04$14,209.524,399View SEC Filing  
3/4/2016Mark D SnyderEVPSell2,940$41.32$121,480.8014,262View SEC Filing  
3/2/2016John L WorkmanDirectorBuy2,500$39.85$99,625.004,500View SEC Filing  
2/19/2016Jerome J LandeDirectorSell1,630,800$38.28$62,427,024.004,000View SEC Filing  
1/4/2016Charles FarkasDirectorBuy332$42.18$14,003.764,064View SEC Filing  
12/11/2015David M BronsonDirectorBuy1,500$41.01$61,515.001,500View SEC Filing  
6/12/2015Jo Ann GoldenDirectorSell1,000$56.03$56,030.00View SEC Filing  
5/29/2015Stephen MandiaDirectorSell14,000$55.62$778,680.00View SEC Filing  
5/6/2015Pat BeyerInsiderBuy5,000$53.36$266,800.00View SEC Filing  
4/30/2015Stephen MandiaDirectorSell3,899$49.97$194,833.03View SEC Filing  
12/12/2014Stephen MandiaDirectorSell4,500$43.23$194,535.00View SEC Filing  
12/1/2014Dirk KuyperDirectorSell1,000$42.85$42,850.00View SEC Filing  
11/19/2014Joseph G DarlingEVPSell4,270$42.00$179,340.00View SEC Filing  
10/29/2014Robert D Shallish JrCFOSell10,410$41.67$433,784.70View SEC Filing  
9/4/2014William AbrahamEVPSell16,062$39.91$641,034.42View SEC Filing  
8/26/2014William AbrahamEVPSell7,423$38.36$284,746.28View SEC Filing  
8/21/2014William AbrahamEVPSell15,986$37.71$602,832.06View SEC Filing  
8/19/2014William AbrahamEVPSell5,312$37.75$200,528.00View SEC Filing  
7/31/2014Curt R HartmanCEOBuy10,000$39.25$392,500.00View SEC Filing  
7/30/2014Bruce DanielsDirectorSell1,600$39.31$62,896.00View SEC Filing  
7/30/2014Joseph J CorasantiCEOSell109,035$39.25$4,279,623.75View SEC Filing  
10/29/2013Joseph J CorasantiCEOSell80,148$36.47$2,922,997.56View SEC Filing  
10/28/2013Bruce DanielsDirectorSell4,500$36.43$163,935.00View SEC Filing  
9/13/2013Joseph CorasantiCEOSell44,852$33.04$1,481,910.08114,148View SEC Filing  
9/11/2013William AbrahamSVPSell7,423$33.48$248,522.0421,659View SEC Filing  
8/15/2013Dirk KuyperDirectorBuy1,000$31.63$31,630.001,000View SEC Filing  
6/7/2013Daniel JonasVPSell2,000$32.42$64,840.00View SEC Filing  
6/4/2013Heather L CohenVPSell1,200$32.59$39,108.00View SEC Filing  
5/31/2013Luke A PomilioVPSell2,556$33.19$84,833.64View SEC Filing  
5/29/2013Heather L CohenVPSell4,514$34.31$154,875.34View SEC Filing  
5/28/2013Robert D Shallish JrCFOSell10,000$34.35$343,500.00View SEC Filing  
2/15/2013Stuart J SchwartzDirectorSell1,000$30.32$30,320.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CONMED (NASDAQ CNMD) News Headlines

Source:
DateHeadline
CONMED Co. (CNMD) Receives Average Rating of "Hold" from AnalystsCONMED Co. (CNMD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 21 at 10:58 AM
5 Reasons Why You Should Buy CONMED (CNMD) Stock Right Now5 Reasons Why You Should Buy CONMED (CNMD) Stock Right Now
finance.yahoo.com - February 15 at 9:00 AM
CONMED Corporation to Present at the Canaccord Genuity Musculoskeletal ConferenceCONMED Corporation to Present at the Canaccord Genuity Musculoskeletal Conference
finance.yahoo.com - February 15 at 9:00 AM
Insider Selling: CONMED Co. (CNMD) CFO Sells 1,962 Shares of StockInsider Selling: CONMED Co. (CNMD) CFO Sells 1,962 Shares of Stock
www.americanbankingnews.com - February 13 at 6:30 PM
Contrasting CONMED (CNMD) and Cytori Therapeutics (CYTX)Contrasting CONMED (CNMD) and Cytori Therapeutics (CYTX)
www.americanbankingnews.com - February 12 at 3:16 PM
$198.04 Million in Sales Expected for CONMED Co. (CNMD) This Quarter$198.04 Million in Sales Expected for CONMED Co. (CNMD) This Quarter
www.americanbankingnews.com - February 9 at 4:34 AM
 Brokerages Anticipate CONMED Co. (CNMD) Will Announce Earnings of $0.43 Per Share Brokerages Anticipate CONMED Co. (CNMD) Will Announce Earnings of $0.43 Per Share
www.americanbankingnews.com - February 7 at 5:10 AM
CONMED Co. (CNMD) CFO Sells $1,142,297.74 in StockCONMED Co. (CNMD) CFO Sells $1,142,297.74 in Stock
www.americanbankingnews.com - February 5 at 3:26 PM
CONMED Corporation to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceCONMED Corporation to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 5 at 8:54 AM
KeyCorp Analysts Lift Earnings Estimates for CONMED Co. (CNMD)KeyCorp Analysts Lift Earnings Estimates for CONMED Co. (CNMD)
www.americanbankingnews.com - February 5 at 6:20 AM
Brokers Offer Predictions for CONMED Co.s FY2018 Earnings (CNMD)Brokers Offer Predictions for CONMED Co.'s FY2018 Earnings (CNMD)
www.americanbankingnews.com - February 5 at 6:20 AM
CONMED (CNMD) Upgraded to "Hold" by BidaskClubCONMED (CNMD) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM
Insider Selling: CONMED Co. (CNMD) Director Sells 3,000 Shares of StockInsider Selling: CONMED Co. (CNMD) Director Sells 3,000 Shares of Stock
www.americanbankingnews.com - February 2 at 9:44 PM
CONMED (CNMD) Stock Rating Upgraded by Zacks Investment ResearchCONMED (CNMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 2 at 4:46 PM
Q1 2018 Earnings Forecast for CONMED Co. Issued By Leerink Swann (CNMD)Q1 2018 Earnings Forecast for CONMED Co. Issued By Leerink Swann (CNMD)
www.americanbankingnews.com - February 2 at 10:28 AM
CONMED Co. to Post Q1 2018 Earnings of $0.43 Per Share, KeyCorp Forecasts (CNMD)CONMED Co. to Post Q1 2018 Earnings of $0.43 Per Share, KeyCorp Forecasts (CNMD)
www.americanbankingnews.com - February 2 at 9:30 AM
Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4
finance.yahoo.com - February 1 at 4:40 PM
Conmed tops Street 4Q forecastsConmed tops Street 4Q forecasts
finance.yahoo.com - February 1 at 8:59 AM
CONMED (CNMD) Posts Quarterly  Earnings Results, Beats Expectations By $0.04 EPSCONMED (CNMD) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - January 31 at 7:26 PM
CONMED (CNMD) Updates FY18 Earnings GuidanceCONMED (CNMD) Updates FY18 Earnings Guidance
www.americanbankingnews.com - January 31 at 5:58 PM
CONMED Corporation Announces Fourth Quarter and Fiscal Year 2017 Financial ResultsCONMED Corporation Announces Fourth Quarter and Fiscal Year 2017 Financial Results
finance.yahoo.com - January 31 at 4:48 PM
Where CONMED Corporation (NASDAQ:CNMD) Stands In Terms Of Earnings Growth Against Its IndustryWhere CONMED Corporation (NASDAQ:CNMD) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - January 31 at 4:48 PM
DENTSPLY SIRONA (XRAY) and CONMED (CNMD) Financial ContrastDENTSPLY SIRONA (XRAY) and CONMED (CNMD) Financial Contrast
www.americanbankingnews.com - January 30 at 5:10 AM
CONMED Co. (CNMD) Receives Average Recommendation of "Hold" from AnalystsCONMED Co. (CNMD) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 10:32 AM
CONMED (CNMD) and CareFusion (CFN) Head to Head ContrastCONMED (CNMD) and CareFusion (CFN) Head to Head Contrast
www.americanbankingnews.com - January 26 at 3:10 PM
DENTSPLY SIRONA (XRAY) vs. CONMED (CNMD) Head-To-Head ComparisonDENTSPLY SIRONA (XRAY) vs. CONMED (CNMD) Head-To-Head Comparison
www.americanbankingnews.com - January 25 at 9:48 AM
CONMED (CNMD) Scheduled to Post Quarterly Earnings on WednesdayCONMED (CNMD) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - January 24 at 3:56 AM
CONMED Co. (CNMD) Expected to Post Earnings of $0.65 Per ShareCONMED Co. (CNMD) Expected to Post Earnings of $0.65 Per Share
www.americanbankingnews.com - January 21 at 9:42 AM
Head-To-Head Review: CONMED (CNMD) and SurModics (SRDX)Head-To-Head Review: CONMED (CNMD) and SurModics (SRDX)
www.americanbankingnews.com - January 20 at 1:10 AM
Factors of Influence in 2018, Key Indicators and Opportunity within United Therapeutics, LTC Properties, WageWorks, Clearwater Paper, United Insurance, and CONMED — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within United Therapeutics, LTC Properties, WageWorks, Clearwater Paper, United Insurance, and CONMED — New Research Emphasizes Economic Growth
finance.yahoo.com - January 18 at 9:46 AM
CONMED Corporation to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on January 31, 2018CONMED Corporation to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on January 31, 2018
finance.yahoo.com - January 17 at 5:33 PM
Zacks Investment Research Lowers CONMED (CNMD) to HoldZacks Investment Research Lowers CONMED (CNMD) to Hold
www.americanbankingnews.com - January 11 at 5:34 PM
CONMED (CNMD) Cut to "Hold" at Zacks Investment ResearchCONMED (CNMD) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 7 at 9:40 PM
Zacks: Analysts Anticipate CONMED Co. (CNMD) Will Post Quarterly Sales of $212.38 MillionZacks: Analysts Anticipate CONMED Co. (CNMD) Will Post Quarterly Sales of $212.38 Million
www.americanbankingnews.com - January 6 at 4:46 AM
CONMED Corporation Appoints Todd W. Garner as Executive Vice President and Chief Financial OfficerCONMED Corporation Appoints Todd W. Garner as Executive Vice President and Chief Financial Officer
finance.yahoo.com - January 2 at 6:50 PM
CONMED Co. (CNMD) Given Average Recommendation of "Hold" by AnalystsCONMED Co. (CNMD) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 2 at 8:26 AM
BidaskClub Downgrades CONMED (CNMD) to Strong SellBidaskClub Downgrades CONMED (CNMD) to Strong Sell
www.americanbankingnews.com - December 28 at 7:56 PM
$212.38 Million in Sales Expected for CONMED Co. (CNMD) This Quarter$212.38 Million in Sales Expected for CONMED Co. (CNMD) This Quarter
www.americanbankingnews.com - December 20 at 2:00 AM
CONMED Corporation to Present at the J.P. Morgan Healthcare ConferenceCONMED Corporation to Present at the J.P. Morgan Healthcare Conference
finance.yahoo.com - December 19 at 5:22 PM
CONMED Corp. : CNMD-US: Dividend Analysis : December 15th, 2017 (record date) : By the numbers : December 19, 2017CONMED Corp. : CNMD-US: Dividend Analysis : December 15th, 2017 (record date) : By the numbers : December 19, 2017
finance.yahoo.com - December 19 at 5:22 PM
CONMED Corporation (CNMD) Expected to Announce Earnings of $0.65 Per ShareCONMED Corporation (CNMD) Expected to Announce Earnings of $0.65 Per Share
www.americanbankingnews.com - December 18 at 11:10 PM
CONMED (CNMD) Downgraded to Sell at BidaskClubCONMED (CNMD) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - December 17 at 5:58 PM
ETFs with exposure to CONMED Corp. : December 14, 2017ETFs with exposure to CONMED Corp. : December 14, 2017
finance.yahoo.com - December 14 at 5:56 PM
CONMED Corporation (CNMD) Receives Consensus Recommendation of "Hold" from AnalystsCONMED Corporation (CNMD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 8 at 8:06 AM
CONMED Corp. breached its 50 day moving average in a Bearish Manner : CNMD-US : December 5, 2017CONMED Corp. breached its 50 day moving average in a Bearish Manner : CNMD-US : December 5, 2017
finance.yahoo.com - December 5 at 10:06 AM
$212.38 Million in Sales Expected for CONMED Corporation (CNMD) This Quarter$212.38 Million in Sales Expected for CONMED Corporation (CNMD) This Quarter
www.americanbankingnews.com - December 2 at 2:50 AM
$0.65 Earnings Per Share Expected for CONMED Corporation (CNMD) This Quarter$0.65 Earnings Per Share Expected for CONMED Corporation (CNMD) This Quarter
www.americanbankingnews.com - November 30 at 9:32 PM
CONMED Corporation (CNMD) Declares $0.20 Quarterly DividendCONMED Corporation (CNMD) Declares $0.20 Quarterly Dividend
www.americanbankingnews.com - November 28 at 4:40 PM
CONMED Corporation (CNMD) Earns "Buy" Rating from Needham & Company LLCCONMED Corporation (CNMD) Earns "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - November 18 at 11:38 AM
ETFs with exposure to CONMED Corp. : November 16, 2017ETFs with exposure to CONMED Corp. : November 16, 2017
finance.yahoo.com - November 16 at 12:56 PM

SEC Filings

CONMED (NASDAQ:CNMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CONMED (NASDAQ:CNMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CONMED (NASDAQ CNMD) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.